Abstract:Susanna S. Park ^ Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA ^ ORCID: 0000-0001-5911-6671. Comment on: Ding X, Sun Z, Guo Y, et al . Inhibition of NF-κB ameliorates aberrant retinal glia activation and inflammatory responses in streptozotocin-induced diabetic rats. Ann Transl Med 2023;11:197. Keywords: Diabetes; microglia; Muller cells; retinal neurodegeneration; vascular endothelial growth factor (VEGF) Submitted Mar 07, 2023. Accepted for publication Apr 30, 2023. Published online May 18, 2023. doi: 10.21037/atm-23-1166 Diabetic retinopathy (DR) is a leading cause of irreversible blindness in adults (1-3). Treatments available to limit vision loss from complications of DR include intravitreal injection of drugs that inhibit vascular endothelial growth factor (VEGF) or inflammation, surgery and retinal laser photocoagulation (3). Despite these interventions, blindness from DR persists since the retinal vasculopathy and neuronal degeneration cannot be reversed. Extensive research has been conducted to decipher the molecular pathways involved in the development of DR in the hopes of finding a cure. Oxidative stress and inflammation are important pathways activated in DR (3). Recent studies indicate that neurodegeneration of retinal ganglion cells and glial cell activation occur before development of retinal vasculopathy and are important early steps involved in the pathogenesis of DR (4). Glial cell activation triggers inflammation and oxidative stress, which in turn worsens DR. In the publication by Ding et al. , retinal glia was targeted to limit retinal neuronal degeneration from DR (5). Muller cells are the principal retinal glial cells that stretch across the thickness of the retina and provide homeostatic and metabolic support to neurons by mediating transcellular ion, water and bicarbonate transport (6). They are components of the neurovascular unit in the retina, regulating the blood-retinal barrier and synaptic activity of retinal neurons. Microglia are resident immune cells contributing to immune surveillance. Microglia, activated by retinal injury, produce proinflammatory mediators and kill degenerating retinal neurons (7). Targeting the retinal glia to limit retinal damage from DR is a novel, logical approach. Ding et al. used a rat model of DR to study the effect of inhibition of nuclear factor-κB (NF-κB) activation via systemic administration of IMD-0354 (5) since NF-κB is a transcription factor that regulates the activation of microglia and Muller cells (8). In addition, in vitro studies were conducted using cultured retinal glial cells to evaluate the effects of IMD-0354. The authors found that the increase in nuclear NF-κB-p65 associated with DR was reduced by IMD-0354 administration. IMD-0354 also inhibited microglia and Muller cell activation and oxidative damage and apoptosis of the retinal neurons associated with DR. Decreased retinal production of VEGF and inflammatory cytokines was also observed. In vitro studies similarly showed that IMD-0354 inhibited the molecular changes associated with high glucose in cultured Muller cells and microglia. The study findings are compelling although many questions remain unanswered. What are long-term effects of inhibiting NF-κB activation on retinal function and development of DR? Since NF-κB is ubiquitously expressed, is systemic inhibition of this factor well tolerated? Since the pathogenesis of DR is complex, further investigation is needed regarding the role of NF-κB and glia in the development of DR. Funding: This work was supported in part by the Barbara A. & Alan M. Roth, MD Endowed Chair of Discovery, Education and Patient Care in Vision Science (SS Park) from the University of California Davis. Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine . The article did not undergo external peer review. Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1166/coif). The author reports contracted research to employer for multicenter clinical trial from industry evaluating intravitreal drugs that inhibit VEGF or inflammation to treat retinopathy. The author has no other conflicts of interest to declare. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replica -Abstract Truncated-

Interaction between microglia and retinal pigment epithelial cells determines the integrity of outer blood-retinal barrier in diabetic retinopathy

IL-10-induced modulation of macrophage polarization suppresses outer-blood-retinal barrier disruption in the streptozotocin-induced early diabetic retinopathy mouse model

Elevated Retinal Retinol-Binding Protein 4 Levels in Diabetic Mice Can Induce Retinal Neurodegeneration Through Microglia

Diabetic Müller-Glial-Cell-Specific Il6ra Knockout Mice Exhibit Accelerated Retinal Functional Decline and Thinning of the Inner Nuclear Layer

Microglia-endothelial cross-talk regulates diabetes-induced retinal vascular dysfunction through remodeling inflammatory microenvironment

Melatonin Maintains Inner Blood–Retinal Barrier by Regulating Microglia via Inhibition of PI3K/Akt/Stat3/NF-κB Signaling Pathways in Experimental Diabetic Retinopathy

Function of Microglia in Diabetic Retinopathy

Suppression of inner blood-retinal barrier breakdown and pathogenic Müller glia activation in ischemia retinopathy by myeloid cell depletion

MEK/ERK/RUNX2 Pathway-Mediated IL-11 Autocrine Promotes the Activation of Muller Glial Cells during Diabetic Retinopathy

Interleukin-17-mediated protective cytokine signaling against degeneration of the retinal pigment epithelium

Integrated multi-omics reveals the activated retinal microglia with intracellular metabolic reprogramming contributes to inflammation in STZ-induced early diabetic retinopathy

Müller Glia Co-Regulate Barrier Permeability with Endothelial Cells in an Vitro Model of Hyperglycemia

Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy

Microvascular destabilization and intricated network of the cytokines in diabetic retinopathy: from the perspective of cellular and molecular components

Natural Flavonoid Galangin Alleviates Microglia-Trigged Blood-Retinal Barrier Dysfunction During the Development of Diabetic Retinopathy.

Retinal perivascular macrophages regulate immune cell infiltration during neuroinflammation in mouse models of ocular disease

Dysregulated CD200-CD200R signaling in early diabetes modulates microglia-mediated retinopathy

Redox Regulation of Immunometabolism in Microglia Underpinning Diabetic Retinopathy

Induction, amplification, and propagation of diabetic retinopathy-associated inflammatory cytokines between human retinal microvascular endothelial and Müller cells and in the mouse retina

Retinal glia and NF-κB in diabetic retinopathy pathogenesis

IL-1β-induced Pericyte Dysfunction with a Secretory Phenotype Exacerbates Retinal Microenvironment Inflammation Via Hes1/STAT3 Signaling Pathway